Pan-cancer analysis indicates that SLC2A3 is aberrantly expressed across multiple tumor types and correlates with poor clinical outcomes, highlighting its potential as a universal marker of metabolic reprogramming and immune regulation in cancer. Here, SLC2A3 is linked to neoplasm.